TITLE

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

AUTHOR(S)
Yeo, Dannel; Hong He; Patel, Oneel; Lowy, Andrew M.; Baldwin, Graham S.; Nikfarjam, Mehrdad; He, Hong
PUB. DATE
January 2016
SOURCE
BMC Cancer;1/16/2016, Vol. 16, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic cancer.Methods: PAK1 expression was measured in pancreatic cancer specimens by immunohistochemistry and in pancreatic cancer cell lines by western blotting. The effect of inhibition of PAK1 by either shRNA knock-down (KD), or by a selective inhibitor, FRAX597, alone or in combination with gemcitabine, on cell proliferation and migration/invasion was measured by thymidine uptake and Boyden chamber assays, respectively. The effect on tumour growth and survival was assessed in orthotopic murine models.Results: PAK1 was expressed in all human pancreatic cancer samples tested, an7d was upregulated in all pancreatic cancer cell lines tested. PAK1 KD inhibited pancreatic cancer cell growth and survival, and increased sensitivity to gemcitabine treatment. AKT activity and HIF1α expression were also inhibited. FRAX597 inhibited pancreatic cancer cell proliferation, survival, and migration/invasion. When combined with gemcitabine, FRAX597 synergistically inhibited pancreatic cancer proliferation in vitro and inhibited tumour growth in vivo.Conclusions: These results implicate PAK1 as a regulator of pancreatic cancer cell growth and survival. Combination of a PAK1 inhibitor such as FRAX597 with cytotoxic chemotherapy deserves further study as a novel therapeutic approach to pancreatic cancer treatment.
ACCESSION #
112326276

 

Related Articles

  • Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Belalcazar, Astrid; Shaib, Walid L.; Farren, Matthew R.; Zhang, Chao; Chen, Zhengjia; Yang, Lily; Lesinski, Gregory B.; El‐Rayes, Bassel F.; Nagaraju, Ganji Purnachandra // Cancer (0008543X);Dec2017, Vol. 123 Issue 24, p4924 

    Background: Heat shock protein 90 (HSP90) and the ubiquitin-proteasome pathway play crucial roles in the homeostasis of pancreatic cancer cells. This study combined for the first time the HSP90 inhibitor ganetespib (Gan) and the proteasome inhibitor carfilzomib (Carf) to target key...

  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. Norris, John D.; Ellison, Stephanie J.; Baker, Jennifer G.; Stagg, David B.; Wardell, Suzanne E.; Sunghee Park; Alley, Holly M.; Baldi, Robert M.; Yllanes, Alexander; Andreano, Kaitlyn J.; Stice, James P.; Lawrence, Scott A.; Eisner, Joel R.; Price, Douglas K.; Moore, William R.; Figg, William D.; McDonnell, Donald P.; Park, Sunghee // Journal of Clinical Investigation;Jun2017, Vol. 127 Issue 6, p2326 

    The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of androgens, has been exemplified by the approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC). Recently, however, it has been...

  • Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. Shimasaki, Takeo; Ishigaki, Yasuhito; Nakamura, Yuka; Takata, Takanobu; Nakaya, Naoki; Nakajima, Hideo; Sato, Itaru; Zhao, Xia; Kitano, Ayako; Kawakami, Kazuyuki; Tanaka, Takuji; Takegami, Tsutomu; Tomosugi, Naohisa; Minamoto, Toshinari; Motoo, Yoshiharu // Journal of Gastroenterology;Mar2012, Vol. 47 Issue 3, p321 

    Background: Pancreatic cancer is obstinate and resistant to gemcitabine, a standard chemotherapeutic agent for the disease. We previously showed a therapeutic effect of glycogen synthase kinase-3β (GSK3β) inhibition against gastrointestinal cancer and glioblastoma. Here, we investigated...

  • Effects of Artesunate on the Invasion of Lung Adenocarcinoma A549 Cells and Expression of ICAM-1 and MMP-9. Xianshan CHEN; Kunyuan HAN; Fengxia CHEN; Congming WU; Weiyi HUANG // Chinese Journal of Lung Cancer;Nov2013, Vol. 16 Issue 11, p567 

    Artesunate, an anti-malarial drug, elicits an inhibitory effect on pulmonary carcinoma. However, the mechanisms of artesunate activity on pulmonary carcinoma have not been completely elucidated. The aim of this study is to investigate the effect of artesunate on the invasion of human lung...

  • miR-17-5p Inhibitor Enhances Chemosensitivity to Gemcitabine Via Upregulating Bim Expression in Pancreatic Cancer Cells. Yan, Hai-jiao; Liu, Wen-song; Sun, Wen-hui; Wu, Jun; Ji, Mei; Wang, Qi; Zheng, Xiao; Jiang, Jing-ting; Wu, Chang-ping // Digestive Diseases & Sciences;Dec2012, Vol. 57 Issue 12, p3160 

    Background: miR-17-5p is reported to be overexpressed in pancreatic cancer, and it plays an important role in carcinogenesis and cancer progression. Gemcitabine is the standard first-line chemotherapeutic agent for pancreatic cancer, however the chemoresistance limits the curative effect. Aims:...

  • Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia. Narlik-Grassow, Maja; Blanco-Aparicio, Carmen; Cecilia, Yolanda; Perez, Marco; Muñoz-Galvan, Sandra; Cañamero, Marta; Carnero, Amancio // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    The Pim proteins are a family of highly homologous protein serine/threonine kinases that have been found to be overexpressed in cancer. Elevated levels of Pim1 kinase were first discovered in human leukemia and lymphomas. However, more recently Pim1 was found to be increased in solid tumors,...

  • Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways. Seong M. Kim; Roy, Saurabh G.; Bin Chen; Nguyen, Tiffany M.; McMonigle, Ryan J.; McCracken, Alison N.; Yanling Zhang; Satoshi Kofuji; Jue Hou; Selwan, Elizabeth; Finicle, Brendan T.; Nguyen, Tricia T.; Ravi, Archna; Ramirez, Manuel U.; Wiher, Tim; Guenther, Garret G.; Mari Kono; Atsuo T. Sasaki; Weisman, Lois S.; Potma, Eric O. // Journal of Clinical Investigation;Nov2016, Vol. 126 Issue 11, p4088 

    Oncogenic mutations drive anabolic metabolism, creating a dependency on nutrient influx through transporters, receptors, and macropinocytosis. While sphingolipids suppress tumor growth by downregulating nutrient transporters, macropinocytosis and autophagy still provide cancer cells with fuel....

  • Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect. Seo, Minsuh; Kim, Jeong-Do; Neau, David; Sehgal, Inder; Lee, Yong-Hwan // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Cancer cells adopt glycolysis as the major source of metabolic energy production for fast cell growth. The HIF-1-induced PFKFB3 plays a key role in this adaptation by elevating the concentration of Fru-2,6-BP, the most potent glycolysis stimulator. As this metabolic conversion has been suggested...

  • Cytotoxic and Antitumor Activity of Lactaptin in Combination with Autophagy Inducers and Inhibitors. Bagamanshina, Anastasia V.; Troitskaya, Olga S.; Nushtaeva, Anna A.; Yunusova, Anastasia Yu; Starykovych, Marina O.; Kuligina, Elena V.; Kit, Yuri Ya; Richter, Max; Wohlfromm, Fabian; Kähne, Thilo; Lavrik, Inna N.; Richter, Vladimir A.; Koval, Olga A. // BioMed Research International;6/17/2019, p1 

    Autophagy is a degradative process in which cellular organelles and proteins are recycled to restore homeostasis and cellular metabolism. Autophagy can be either a prosurvival or a prodeath process and remains one of the most fundamental processes for cell vitality. Thus autophagy modulation is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics